Ambience Healthcare vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ambience Healthcare raised $370M (~$1B valuation) and hit $30M ARR with ambient AI documentation across 100+ specialties, eliminating the documentation burden driving clinician burnout.
About
Ambience Healthcare was founded in 2020 in San Francisco with a mission to eliminate the documentation burden that drives clinician burnout and degrades patient care quality across health systems. The company builds ambient AI documentation technology that listens to clinical encounters across more than 100 medical and surgical specialties, generating accurate, complete clinical notes in the background without requiring clinicians to dictate or type. Ambience's core technology leverages large language models purpose-trained on clinical language, specialty-specific note structures, and electronic health record formatting requirements to produce documentation that is ready for review with minimal editing.\n\nAmbience's platform is deployed across health systems ranging from large academic medical centers to independent practices, covering more than 100 specialties including primary care, surgery, oncology, behavioral health, and pediatrics. Unlike narrower documentation tools that focus on a single specialty or encounter type, Ambience's breadth allows health systems to deploy a single solution enterprise-wide. The platform integrates with major EHR systems including Epic and Cerner, embedding documentation into existing clinical workflows without requiring behavior change from clinicians. Ambience achieved approximately $30 million in annual recurring revenue as of May 2025.\n\nAmbience Healthcare has raised approximately $370 million in total funding, approaching a $1 billion valuation, from investors including Andreessen Horowitz and other leading healthcare-focused venture firms. The company competes with Nuance DAX, Suki, and Nabla in the ambient documentation space but differentiates through its specialty breadth, enterprise EHR integration depth, and strong health system relationships. As health systems face escalating clinician burnout and documentation-driven inefficiency, Ambience's full-enterprise approach positions it as a platform of record for ambient clinical intelligence.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.